New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer

Total Page:16

File Type:pdf, Size:1020Kb

New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer Laura C. Kennedy, MD, PhD, and Ingrid A. Mayer, MD, MSCI Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee Corresponding author: Abstract: Endocrine-based treatments are the backbone of initial Ingrid Mayer, MD therapy for advanced hormone receptor–positive breast cancers. Professor of Medicine Developing new therapeutic strategies to address resistance to Vanderbilt University Medical Center/ endocrine therapy is an area of active research. In this review, we Vanderbilt-Ingram Cancer Center 2220 Pierce Ave 777 PRB discuss targeted therapies that are currently the standard of care, Nashville, TN 37232 as well as agents that are at present under investigation as potential Tel: (615) 936-2033 treatments for advanced hormone receptor–positive breast cancer. Email: [email protected] Introduction Hormone receptor–positive (HR+) breast cancers are the most com- monly identified subtype of breast cancer, accounting for about 70% of early and de novo metastatic breast cancer diagnoses.1,2 Estrogen is the main driver of cancer cell proliferation in HR+ breast cancer. Upon binding with estrogen, the estrogen receptor (ER) acts as both a direct transcription factor and a regulator of other transcription factors to drive cell proliferation.3 Therefore, a key component in the initial treatment of metastatic HR+ breast cancer is estrogen depriva- tion. In the treatment-naive state, most advanced HR+ breast cancers are sensitive to estrogen blockade with either an aromatase inhibitor (AI; eg, letrozole, anastrozole, or exemestane) for postmenopausal women or an AI plus ovarian suppression for premenopausal women. Resistance to endocrine therapy is an inevitable development, however, and may be acquired or primary. Acquired resistance is defined as disease progression beyond 2 years of adjuvant endocrine therapy or after at least 6 months of endocrine therapy in the setting of advanced breast cancer; primary resistance is defined as disease progression within 2 years of adjuvant endocrine therapy or after less than 6 months of endocrine therapy in the advanced setting.4 In acquired resistance, mutations or genomic alterations develop owing to therapy selection pressures that favor continued cancer cell proliferation despite the loss of primary estrogen signaling. In pri- mary resistance, which affects a smaller pool of patients, mutations or genomic alterations are present in the untreated breast cancer.5 Examples of acquired genomic alterations leading to endocrine therapy resistance include mutations in the estrogen receptor alpha Keywords (ESR1) gene and mutations or alterations leading to an increased acti- Endocrine resistance, hormone receptor–positive vation of growth factor pathways, such as phosphoinositide 3-kinase breast cancer, targeted therapy (PI3K). Primary genomic alterations include loss of p16, fibroblast Clinical Advances in Hematology & Oncology Volume 19, Issue 8 August 2021 511 KENNEDY AND MAYER growth factor receptor (FGFR) gene amplifications, and growth and contributing to endocrine resistance.8,10 The MYC amplification or overexpression.5-8 addition of specific inhibitors of CDK4/6 (palbociclib In this review, we discuss the development of current [Ibrance, Pfizer], ribociclib [Kisqali, Novartis], abemac- and investigational targeted therapies for patients with iclib [Verzenio, Lilly], and dalpiciclib [SHR6390]) to advanced HR+ breast cancer. an endocrine backbone (an AI or fulvestrant) prolongs endocrine sensitivity, and CDK4/6 inhibitors are now Standard-of-Care Strategies to Address recommended as part of first-line therapy for patients Endocrine Resistance with metastatic HR+ disease. Palbociclib, ribociclib, abe- maciclib, and dalpiciclib all prolong progression-free sur- Genomic Alterations in HR+ Breast Cancer vival (PFS) in the first- or second-line setting,11-15 and an Resistance to endocrine therapy can be related to a vari- overall survival (OS) benefit has been shown in the first- ety of genomic alterations in several different pathways line setting for premenopausal women,12 although it has (Figure). One of the challenges of addressing the genomic not yet been reported in postmenopausal women.11,16,17 alterations in advanced HR+ breast cancer is the diversity In the second-line setting, the combination of either of mutations that can be implicated in treatment resis- fulvestrant and abemaciclib or fulvestrant and ribociclib tance. Several breast cancer cell pathways can be altered prolonged OS in the intention-to-treat population and to favor cancer progression and carcinogenesis, and many in patients with endocrine-resistant disease.14,18 Although of the genomic alterations that are seen in advanced HR+ the combination of fulvestrant and palbociclib did not breast cancer occur in 10% or fewer of patients.5,7 result in a significant OS difference in the intention- The major steps in the ER pathway include estrogen to-treat population, it did appear to increase OS in the binding to the ER with signaling through cyclin-depen- patients with endocrine-sensitive breast cancer on sub- dent kinases 4 and 6 (CDK4/6) and cyclin D, leading group analysis.13 to the phosphorylation of retinoblastoma protein (Rb). Evidence suggests that patients with HR+ breast Phosphorylation of Rb releases the E2F transcription fac- cancer that has progressed during endocrine therapy and tor and triggers progression from G1 to S in the cell cycle, CDK4/6 inhibitor treatment could still benefit from an leading to cancer cell proliferation and tumor growth. endocrine-based regimen if the correct resistance mecha- Multiple pathways and proteins other than direct binding nism were addressed. In a small study looking at patients with the ER route through CDK4/6 and lead to Rb phos- treated with letrozole/palbociclib, new ESR1 mutations phorylation.. These include alterations such as inactiva- developed over the course of treatment.19 Another tion of p16, which inhibits CDK4/6, a common finding correlative study (PALOMA-3) looking at the cell-free in breast cancer9; mutations in PIK3CA and TP53, which circulating tumor DNA of patients treated with fulves- are found in about 40% of patients with metastatic HR+ trant/palbociclib found that 30% of them had acquired breast cancer; and alterations in proteins such as PTEN, new mutations in genes such as ESR1, PI3KCA, ERBB2, ERBB2, MYC, and ARID1A, which occur in 10% or FGFR, and Rb over the course of treatment.20 Interestingly, fewer patients but still drive cell proliferation.5,7 the mutational profile of patients treated with fulvestrant These alterations ultimately favor the development was the same as that of the patients treated with fulves- of endocrine therapy resistance (ie, continued cellular trant/palbociclib except for the presence of Rb mutations, proliferation despite endocrine blockade). Some of the which developed in 5% of patients after treatment with propensities to resistance are present in untreated pri- fulvestrant/palbociclib but not in those treated with mary HR+ breast cancer, such as genomic alterations fulvestrant alone. This finding suggests that treatment in PIK3CA, HER2, AKT, and FGFR,5,7 whereas others is pressuring both the development of mutations such develop through selection pressure with endocrine treat- as those in ESR1 that will directly evade the endocrine ment. Mutations in ESR1 are one of the more common backbone and alterations in other pathways that drive treatment-acquired alterations. ESR1 mutations are pres- breast cancer proliferation, rather than that the breast ent in only 3% of untreated HR+ breast cancers, but in cancer is developing independence from estrogen-based 25% of AI-treated HR+ breast cancers.7 Selective estrogen signaling. With continued tumor dependence on estrogen receptor downregulators (SERDs) such as fulvestrant were signaling, it is reasonable to posit that additional endo- subsequently developed to address ESR1 mutations. crine-based treatments could be effective if paired with the correct adjunct treatment to address the resistant CDK4/6 Inhibitors pathway. This idea was supported by the results of the Inactivation of p16 and modifications in the Rb/CDK4/ BOLERO-2 randomized phase 3 trial, which showed that CDK6/cyclin D pathway are present in approximately the combination of everolimus, a mammalian target of 50% of primary HR+ breast cancers, driving cancer cell rapamycin (mTOR) inhibitor, plus exemestane improved 512 Clinical Advances in Hematology & Oncology Volume 19, Issue 8 August 2021 ENDOCRINE-RESISTANT HORMONE RECEPTOR–POSITIVE BREAST CANCER Estrogen signaling IGFR-1 IGFR-2 HER2 HER3 ESR1 mutation Downregulation of ERα expression p16 FGFR Inactivation of p16 Loss of p16 binding owing to CDK4 mutation PI3K CDK4/6 ↑ CDK4 ↑ Cyclin D PTEN Cyclin D Alterations noted in untreated ER+ BC Alterations noted in treated ER+ BC AKT mTORC P Rb PTEN inactivation Rb PIK3CA mutations E2F Nucleus AKT1 mutations AKT2 and AKT3 amplications Aurora Cell cycle A Functional loss of Rb progression E2F and cell growth Figure. Estrogen receptor signaling in HR+ breast cancer. AKT, RAC-alpha serine/threonine protein kinase; BC, breast cancer; CDK4/6, cyclin-dependent kinases 4 and 6; ER+, estrogen receptor–positive; ERα, estrogen receptor alpha; ESR1, estrogen receptor alpha gene; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGFR-1, insulin-like growth factor receptor 1; mTORC, mammalian
Recommended publications
  • Proteomics and Drug Repurposing in CLL Towards Precision Medicine
    cancers Review Proteomics and Drug Repurposing in CLL towards Precision Medicine Dimitra Mavridou 1,2,3, Konstantina Psatha 1,2,3,4,* and Michalis Aivaliotis 1,2,3,4,* 1 Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; [email protected] 2 Functional Proteomics and Systems Biology (FunPATh)—Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece 3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece 4 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology, GR-70013 Heraklion, Greece * Correspondence: [email protected] (K.P.); [email protected] (M.A.) Simple Summary: Despite continued efforts, the current status of knowledge in CLL molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise. Proteomics ap- proaches combined with advanced bioinformatics and drug repurposing promise to shed light on the complex proteome heterogeneity of CLL patients and mitigate, improve, or even eliminate the knowledge stagnation. In relation to this concept, this review presents a brief overview of all the available proteomics and drug repurposing studies in CLL and suggests the way such studies can be exploited to find effective therapeutic options combined with drug repurposing strategies to adopt and accost a more “precision medicine” spectrum. Citation: Mavridou, D.; Psatha, K.; Abstract: CLL is a hematological malignancy considered as the most frequent lymphoproliferative Aivaliotis, M. Proteomics and Drug disease in the western world. It is characterized by high molecular heterogeneity and despite the Repurposing in CLL towards available therapeutic options, there are many patient subgroups showing the insufficient effectiveness Precision Medicine.
    [Show full text]
  • Bosutinib (Bosulif®) (“Boe SUE Ti Nib”)
    Bosutinib (Bosulif®) (“boe SUE ti nib”) How drug is given: By mouth Purpose: To stop the growth of cancer cells in chronic myelogenous leukemia (CML). How to take this drug 1. Take this medication with food. 2. Swallow each tablet whole; do not crush or chew. IF you have trouble swallowing the tablet, the pharmacist will give you specific instructions. 3. IF you miss a dose, take it as soon as possible. However, if it is less than 12 hours until your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double dose. 4. Wash hands after taking the medication. Avoid handling crushed or broken tablets. 5. Do not drink grapefruit juice or eat grapefruit. Also, do not take St. John’s wort. Consuming these may increase the amount of medication in your body and worsen side effects. 6. Bosutinib can interFere with many drugs, which may change how this works in your body. Talk with your doctor before starting any new drugs, including over the counter drugs, natural products, herbals or vitamins. This includes drugs such as Prilosec™. Storage • Store this medication at room temperature 68-77°F (20-25°C), away From heat, moisture, and direct light. Keep this medicine in its original container, out oF reach oF children and pets. Things that may occur during treatment 1. Loose stools or diarrhea may occur within a few days after the drug is started. You may take loperamide (Imodium A-D®) to help control diarrhea. You may buy this at most drug stores.
    [Show full text]
  • The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer Scott F
    MOLECULAR CANCER THERAPEUTICS | REVIEW The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer Scott F. Schoninger1 and Stacy W. Blain2 ABSTRACT ◥ CDK4 inhibitors (CDK4/6i), such as palbociclib, ribociclib, benefit from these agents, often switching to chemotherapy and abemaciclib, are approved in combination with hormonal within 6 months. Some patients initially benefit from treatment, therapy as a front-line treatment for metastatic HRþ,HER2- but later develop secondary resistance. This highlights the need breast cancer. Their targets, CDK4 and CDK6, are cell-cycle for complementary or companion diagnostics to pinpoint – regulatory proteins governing the G1 S phase transition across patients who would respond. In addition, because CDK4 is a many tissue types. A key challenge remains to uncover biomar- bona fide target in other tumor types where CDK4/6i therapy is kers to identify those patients that may benefit from this class of currently in clinical trials, the lack of target identification may drugs. Although CDK4/6i addition to estrogen modulation ther- obscure benefit to a subset of patients there as well. This review apy essentially doubles the median progression-free survival, summarizes the current status of CDK4/6i biomarker test devel- overall survival is not significantly increased. However, in reality opment, both in clinical trials and at the bench, with particular only a subset of treated patients respond. Many patients exhibit attention paid to those which have a strong biological basis as primary resistance to CDK4/6 inhibition and do not derive any well as supportive clinical data. Introduction well (7). Although these results are promising, the clinical use of CDK4/6 inhibitors is confounded by the high individual variability in Breast cancer is the most common women's cancer worldwide, clinical response.
    [Show full text]
  • Systematic Review: Targeting HER2 in Bladder Cancer
    Bladder Cancer 5 (2019) 1–12 1 DOI 10.3233/BLC-180196 IOS Press Systematic Review Systematic Review: Targeting HER2 in Bladder Cancer Vadim S. Koshkina, Peter O’Donnellb,EvanY.Yuc and Petros Grivasd,∗ aDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, CA, USA bDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA cDepartment of Medicine, Division of Oncology, Clinical Research Director, Fred Hutchinson Cancer Research Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA dDepartment of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA Received 23 August 2018 Accepted 22 November 2018 Abstract. Background: HER2 (ErbB2) is a receptor of the Human Epidermal Growth Factor Receptor (HER) family whose role in oncogenesis of numerous malignancies is well described. Drugs targeting HER2 are currently approved in breast and gastroesophageal cancers while pan-HER targeting agents are being evaluated in multiple malignancies. HER2 genomic alterations are commonly described in urothelial cancer and multiple trials have assessed the efficacy of anti-HER2 agents in both muscle-invasive and metastatic urothelial carcinoma. Objective: To review prospective clinical trials of therapeutic agents with HER2–targeting activity in patients with bladder cancer. Methods: A systematic search of PubMed, ASCO abstracts and Clinicaltrials.gov was performed to identify studies of HER2–targeting agents in bladder cancer. Reported results from prospective trials were reviewed and summarized. Results: Eleven prospective clinical trials with reported results were identified that investigated activity of trastuzumab, lapatinib, neratinib, afatinib, or autologous cellular immunotherapy, (DN24–02), in various bladder cancer treatment settings.
    [Show full text]
  • The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
    Lindström and Friedman BMC Cancer (2020) 20:397 https://doi.org/10.1186/s12885-020-06782-9 RESEARCH ARTICLE Open Access The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib H. Jonathan G. Lindström and Ran Friedman* Abstract Background: Chronic myeloid leukaemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib–dasatinib, imatinib–asciminib and dasatinib–asciminib combinations and calculated combination index graphs for each case. Moreover, using the median–effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition.
    [Show full text]
  • RB1 Dual Role in Proliferation and Apoptosis: Cell Fate Control and Implications for Cancer Therapy
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 20 RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy Paola Indovina1,2, Francesca Pentimalli3, Nadia Casini2, Immacolata Vocca3, Antonio Giordano1,2 1Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 2 Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, Italy 3Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fodazione G. Pascale” – IRCCS, Naples, Italy Correspondence to: Antonio Giordano, e-mail: [email protected] Keywords: RB family, apoptosis, E2F, cancer therapy, CDK inhibitors Received: May 14, 2015 Accepted: June 06, 2015 Published: June 18, 2015 ABSTRACT Inactivation of the retinoblastoma (RB1) tumor suppressor is one of the most frequent and early recognized molecular hallmarks of cancer. RB1, although mainly studied for its role in the regulation of cell cycle, emerged as a key regulator of many biological processes. Among these, RB1 has been implicated in the regulation of apoptosis, the alteration of which underlies both cancer development and resistance to therapy. RB1 role in apoptosis, however, is still controversial because, depending on the context, the apoptotic cues, and its own status, RB1 can act either by inhibiting or promoting apoptosis. Moreover, the mechanisms whereby RB1 controls both proliferation and apoptosis in a coordinated manner are only now beginning to be unraveled. Here, by reviewing the main studies assessing the effect of RB1 status and modulation on these processes, we provide an overview of the possible underlying molecular mechanisms whereby RB1, and its family members, dictate cell fate in various contexts.
    [Show full text]
  • Palbociclib for Male Patients with Metastatic Breast Cancer
    Author Manuscript Published OnlineFirst on October 24, 2019; DOI: 10.1158/1078-0432.CCR-19-2580 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. CCR-19-2580 Title: FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer Authors: Suparna Wedam1*, Lola Fashoyin-Aje1*, Erik Bloomquist1, Shenghui Tang1, Rajeshwari Sridhara1, Kirsten B. Goldberg2, Marc R. Theoret1, Laleh Amiri-Kordestani1, Richard Pazdur1,2, Julia A. Beaver1 Authors’ Affiliation: 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 2Oncology Center of Excellence, U.S. Food and Drug Administration Running Title: FDA Approval of Palbociclib for Male Breast Cancer Corresponding Author: Suparna Wedam, Office of Hematology and Oncology Products, CDER, U.S. Food and Drug Administration, WO22 Room 2112, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Phone: 301-796-1776 Fax: 301-796-9909. Email: [email protected] *: SW and LF-A contributed equally to this publication. Note: This is a U.S. Government work. There are no restrictions on its use. Disclosure of Potential Conflicts of Interest: The authors report no financial interests or relationships with the commercial sponsors of any products discussed in this report. Word count: Abstract, 187. Text: 2836. Tables: 1. Figures: 1. References: 17 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 24, 2019; DOI: 10.1158/1078-0432.CCR-19-2580 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract On April 4, 2019, the Food and Drug Administration (FDA) approved a supplemental new drug application for palbociclib (IBRANCE®), to expand the approved indications in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (MBC) in combination with an aromatase inhibitor or fulvestrant, to include men.
    [Show full text]
  • Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
    Bladder Cancer 5 (2019) 87–102 87 DOI 10.3233/BLC-180205 IOS Press Review Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer Tony Ibrahima, Marco Gizzib, Ratislav Bahledac and Yohann Loriota,d,∗ aD´epartement de M´edecine Oncologique, Gustave Roussy, Universit´e Paris-Sud, Universit´e Paris-Saclay, Villejuif, France bDepartment of Medical Oncology. Grand Hˆopital de Charleroi, Charleroi, Belgium cDrug Development Department (DITEP), Gustave Roussy, Villejuif France dInserm 981, Universit´e Paris-Sud, Universit´e Paris Saclay, Villejuif, France Received: 29 November 2018 Accepted: 4 March 2019 Abstract. The fibroblast growth factor receptor 3 (FGFR3) plays critical roles in driving oncogenesis of a subset of patients with urothelial carcinomas (UC). Growing evidence from preclinical studies suggests that FGFR3 inhibition can reduce proliferation and survival in vitro and in vivo models of FGFR3-altered UC. Early clinical trials investigating selective FGFR3 inhibitor have reported preliminary signs of antitumor activity in advanced UC patients with selected FGFR3 mutations or fusions. Currently, phase 3 trials with erdafitinib and rogaratinib are enrolling patients with known FGFR3 alterations. Future combinations with targeted therapies or immune checkpoint inhibitors may increase the efficacy of selective FGFR3 inhibitors. Herein, we discuss current clinical development of FGFR3 inhibitors as well as unsolved questions with regards to patient selection, management of toxicities and mechanisms of resistance to selective FGFR3 inhibitors. Keywords: Urothelial cancer, bladder cancer, fibroblast growth factor 3, tyrosine kinase INTRODUCTION the treated patients [1–11]. Innovative strategies aim- ing to improve metastatic UC treatment efficacy have Metastatic urothelial carcinoma (UC) is frequent learned from targeted therapies in solid tumors such and has a poor prognosis.
    [Show full text]
  • Second Generation Inhibitors of BCR- ABL for the Treatment of Imatinib- Resistant Chronic Myeloid Leukaemia
    REVIEWS Second generation inhibitors of BCR- ABL for the treatment of imatinib- resistant chronic myeloid leukaemia Ellen Weisberg*, Paul W. Manley‡, Sandra W. Cowan-Jacob§, Andreas Hochhaus|| and James D. Griffin¶ Abstract | Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein. However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance. Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib- resistant CML. Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance. The BCR-ABL oncogene, which is the product of the design of new drugs to circumvent resistance, and Philadelphia chromosome (Ph) 22q, encodes a chimeric several new agents have been developed specifically BCR-ABL protein that has constitutively activated ABL for this purpose. These compounds have been well tyrosine kinase activity; it is the underlying cause of characterized for efficacy against the mutant enzymes chronic myeloid leukaemia (CML)1–3. Whereas the 210 in preclinical studies, and impressive therapeutic activ- kDa BCR-ABL protein is expressed in patients with ity has now been reported for two second generation CML, a 190 kDa BCR-ABL protein, resulting from an drugs in phase I and II clinical trials in patients with *Dana Farber Cancer alternative breakpoint in the BCR gene, is expressed in imatinib-resistant CML.
    [Show full text]
  • New ADC Shrinks HER2-Positive Tumors
    Published OnlineFirst August 2, 2019; DOI: 10.1158/2159-8290.CD-NB2019-089 NEWS IN BRIEF he says, “I can’t cancer, and 17 had HER2-low HR- fathom that cost.” negative breast cancer. The remaining Cytoplasm –Elie Dolgin n 47 patients had gastric, urothelial, or endometrial tumors. Eye-related side effects were again New ADC prevalent: 71% of patients were Shrinks affected by problems such as conjunc- tivitis, keratitis, and dry eye. These Nuclear pore HER2- adverse effects have been seen with complex Positive other ADCs—although they haven’t Tumors been described with T-DM1—but the mechanism remains unclear, says A novel co-author Philippe Aftimos, MD, of Nucleus antibody–drug the Jules Bordet Institute and the Free conjugate (ADC) University of Brussels in Belgium. Tumor suppressor protein Selective inhibitor of triggers responses nuclear export inhibitor The ADC produced partial + eiF4E-bound mRNA in patients with Regulatory factor XPO1 responses in 33% of the patients with HER2-expressing HER2-positive metastatic breast breast cancer Selinexor is a selective inhibitor of nuclear export. By blocking XPO1, it cancer; 28% with HER2-low, HR- prevents molecular cargo from moving through the nuclear pore complex, and other solid positive metastatic breast cancer; and causing cell-cycle arrest, apoptosis, and other antitumor activity. (Courtesy tumors, a phase I 40% with HER2-low, HR-negative of Karyopharm Therapeutics; modified with permission.) clinical trial metastatic breast cancer. The median indicates (Lancet progression-free survival for these Oncol 2019;20:1124–35). The drug commonly experienced side effects three groups was 7.6 months, such as thrombocytopenia, hypona- could become a new treatment for 4.1 months, and 4.9 months, respec- tremia, anemia, and nausea.
    [Show full text]
  • A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-Positive Breast Cancer with Brain Metastasis
    IRB #: STU00202582-CR0003 Approved by NU IRB for use on or after 1/28/2019 through 1/27/2020. A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-positive Breast Cancer with Brain Metastasis Principal Investigator: Massimo Cristofanilli, MD Professor of Medicine Associate Director of Translational Research and Precision Medicine Department of Medicine-Hematology and Oncology Robert H Lurie Comprehensive Cancer Center Feinberg School of Medicine 710 N Fairbanks Court, Olson Building, Suite 8-250A Chicago, IL 60611 Tel: 312-503-5488 Email: [email protected] NU Sub-Investigator(s): Northwestern University Robert H. Lurie Comprehensive Cancer Center Priya Kumthekar, MD Jonathan Strauss Luis Blanco Sofia Garcia Northwestern Lake Forest Hospital Valerie Nelson, MD Affiliate Site PIs: Jenny Chang, MD Houston Methodist Hospital/Houston Methodist Cancer Center 6445 Main Street, P24-326 Houston, Texas 77030 Tel: 713-441-9948 [email protected] Biostatistician: Alfred Rademaker [email protected] Study Intervention(s): Palbociclib (Ibrance) IND Number: Exempt IND Holder: N/A Funding Source: Pfizer Version Date: August 15, 2017 (Amendment 5) Coordinating Center: Clinical Research Office Robert H. Lurie Comprehensive Cancer Center Northwestern University 676 N. St. Clair, Suite 1200 Chicago, IL 60611 http://cancer.northwestern.edu/CRO/index.cfm 1 Version :08.15.2017 IRB #: STU00202582-CR0003 Approved by NU IRB for use on or after 1/28/2019 through 1/27/2020. Table of Contents STUDY SCHEMA ...........................................................................................................................
    [Show full text]
  • | TIME TRIALS February 2021 Provides You Access to a Network of Just-In-Time Biomarker-Driven Trials for Your Patients
    Your organization has enrolled in the TIME TrialTM Network, which | TIME TRIALS February 2021 provides you access to a network of just-in-time biomarker-driven trials for your patients. Studies currently enrolling in the TIME TrialTM Program: SOLID TUMOR SOLID TUMOR CONT. Elevation ELVAP-001-01 Ideaya IDE196-001 GNAQ/11 hotspot mutation (CRESTONE) Phase I/II At least 1 prior standard therapy; NRG1 fusion Phase II NCT03947385 No prior treatment with a PKC At least 1 prior standard therapy NCT04383210 IDE196 inhibitor Seribantumab Janssen CAN2002 (RAGNAR) FGFR 1-4 fusions & specified Phase II mutations BREAST NCT04083976 At least 1 prior standard therapy JNJ-42756493 (Erdafitinib) Excludes Bladder Cancer HER2-, ER+ & ESR1 mutations Sermonix SMX 18-001 (ELAINE I) Progression following AI in Phase II Turning Point TPX-0005-01 combination with a CDK 4/6 inhibitor; (TRIDENT) NCT03781063 NTRK 1-3 fusions No more than 1 prior systemic Phase II Lasofoxifene or Fulvestrant Allowed up to 2 prior TRK TKIs chemotherapy NCT03093116 TPX-0005 (Repotrectinib) Sermonix SMX 20-001 (ELAINE II) HER2-, ER+ & ESR1 mutations Phase II Progression following first or second- Blueprint BLU-667-101 (ARROW) RET fusion NCT04432454 line hormone therapy; No more than 1 Phase I/II At least 1 prior standard therapy; no Lasofoxifene & Abemaciclib prior systemic chemotherapy NCT03037385 prior treatment with a selective RET Pralsetinib (BLU-667) inhibitor ; Excludes MTC and NSCLC Ayala AL-TNBC-01 (TENACITY) Notch Activation Phase II No more than three lines of systemic Merus
    [Show full text]